Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29451773 | 1.00 | HSD17B10 (0.60) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL1190831 | 0.84 | PKM (0.58) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL2908032 | 0.78 | PKM (0.51) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL3281437 | 0.76 | HSD17B10 (1.00) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL23027798 | 0.75 | LMNA (0.78) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL17261495 | 0.74 | PKM (0.72) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL1786217 | 0.73 | HSD17B10 (0.62) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL29451720 | 0.73 | PKM (0.70) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL4604023 | 0.73 | PKM (0.70) | HSD17B10PKMMAPTPOLBMEN1 | |
| SCHEMBL6123101 | 0.73 | GRM5 (0.44) | HSD17B10PKMMAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960171-B1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | UNIV CHINA MEDICAL (TW) | 2025-01-01 | — | — | EP | claimed |
| US-20220202783-A1 | Use Of ADAM9 Inhibitor As Immunomodulator | CHINA MEDICAL UNIVERSITY (TW) | 2022-06-30 | — | — | US | claimed |
| US-11357759-B2 | Composition including ADAM9 inhibitor and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2022-06-14 | — | — | US | claimed |
| CN-114173778-A | Use of ADAM9 inhibitors as immunomodulators | 洪明奇 | 2022-03-11 | — | — | CN | claimed |
| EP-3960171-A1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | China Medical University (TW) | 2022-03-02 | — | — | EP | claimed |
| US-20210052562-A1 | Composition Including ADAM9 Inhibitor And The Use Thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-02-25 | — | — | US | claimed |
| WO-2020216319-A1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | 中国医药大学 | 2020-10-29 | — | — | WO | claimed |
| CN-111655256-A | ADAM9 inhibitors and uses thereof | 中国医药大学 | 2020-09-11 | — | — | CN | claimed |
| EP-3700521-A1 | ADAM9 inhibitors and the uses thereof | China Medical University (TW) | 2020-09-02 | — | — | EP | claimed |
| EP-3960171-B1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | UNIV CHINA MEDICAL (TW) | 2025-01-01 | — | — | EP | disclosed |
| CN-114173778-B | Application of ADAM9 inhibitor in preparation of medicines for preparing immunomodulators | 洪明奇 | 2024-12-27 | — | — | CN | disclosed |
| US-20220202783-A1 | Use Of ADAM9 Inhibitor As Immunomodulator | CHINA MEDICAL UNIVERSITY (TW) | 2022-06-30 | — | — | US | disclosed |
| CN-114173778-A | Use of ADAM9 inhibitors as immunomodulators | 洪明奇 | 2022-03-11 | — | — | CN | disclosed |
| EP-3960171-A1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | China Medical University (TW) | 2022-03-02 | — | — | EP | disclosed |
| EP-3700521-A1 | ADAM9 inhibitors and the uses thereof | China Medical University (TW) | 2020-09-02 | — | — | EP | disclosed |
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1644320-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005009941-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357759-B2 | Composition including ADAM9 inhibitor and the use thereof | ADAM9, ADAM8, ADAM17 | HSD17B10 247/4885PKM 2653/4885MAPT 1737/4885 |
| US-20220202783-A1 | Use Of ADAM9 Inhibitor As Immunomodulator | ADAM9, ADAM17, ADAM10 | HSD17B10 630/4885PKM 3832/4885MAPT 3674/4885 |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | HSD17B10 2457/4885PKM 2682/4885MAPT 2820/4885 |
| US-20210052562-A1 | Composition Including ADAM9 Inhibitor And The Use Thereof | ADAM9, ADAM8, ADAM17 | HSD17B10 247/4885PKM 2653/4885MAPT 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.